Cyclophosphamide
For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.
Active substance: Cyclophosphamide
Examples of brand names: Endoxan [DE]
ATC code: L01AA01
Main use (for orientation): Oncology; autoimmune diseases
Documented research summary
Historical preliminary human pharmacokinetics found no apparent change with THC, but precision was low and this does not establish safety for current CBD doses. Preclinical combinations show model-dependent neuroprotection/uroprotection or cell synergy, without clinical efficacy evidence.
Uncertainties and limitations
Cyclophosphamide injection preparation for human use; no claim of equivalence with oral formulations.
Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.
Separately recorded findings
5 separately recorded findings. Each statement applies to its documented study context.
THC – clinically investigated
Finding ID: B0217
Type of result: Clinical evidence – limited
Observation: Preliminary investigation found no apparent change in cyclophosphamide pharmacokinetics; half-life difference not significant.
Mechanism: Clinical pharmacokinetics
Study type: Historical exploratory human pharmacokinetics
Context studied: Half-life 7.7±3.6 hours without versus 5.25±2.6 hours with THC according to the abstract.
Clinical interpretation: Context-specific evidence
Limitations and uncertainties: Small/imprecisely described sample; not evidence for all cannabinoids, doses or regimens.
Original sources for this finding: Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. [BMED6271847]
CBD – laboratory and animal studies
Finding ID: B0218
Type of result: Preclinical evidence
Observation: CBD attenuated model-related cognitive or bladder injury in separate mouse/rat experiments.
Mechanism: Neuroprotection/uroprotection
Study type: Animal models
Context studied: Doxorubicin plus cyclophosphamide cognition model, orally 20 mg/kg; other studies intraperitoneal or intravesical.
Clinical interpretation: Model finding, not a recommendation for use
Limitations and uncertainties: Different models and routes; no clinical protection or oncological benefit established.
Original sources for this finding: Cannabidiol alleviates chemotherapy-induced cognitive decline and neuropathology. [BMED42202974]; CBD Promotes Structural and Functional Epithelial Restoration and Alleviates Inflammation in a Mouse Model of Interstitial Cystitis. [BMED42076110]; Intravesical Cannabidiol for Inflammation and Pain in Interstitial Cystitis/Bladder Pain Syndrome via TLR4/NF-κB and TRPV1 Modulation. [BMED41508393]
CBD/THC – laboratory and animal studies
Finding ID: B0219
Type of result: Preclinical evidence
Observation: Some cell synergy; no survival benefit in orthotopic medulloblastoma/ependymoma mouse models.
Mechanism: Antitumour combination
Study type: Cell and animal models
Context studied: Negative in-vivo result explicitly included.
Clinical interpretation: Model finding, not a recommendation for use
Limitations and uncertainties: Do not infer clinical efficacy from cell synergy.
Original sources for this finding: Assessment of Cannabidiol and Δ9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma. [BMED33477420]
THC/cannabis extract – laboratory and animal studies
Finding ID: B0220
Type of result: Preclinical evidence
Observation: THC reduced conditioned defensive/taste-aversion responses in rodents; cannabis extract reduced kaolin intake in a rat model.
Mechanism: Antiemetic supportive effect
Study type: Animal models
Context studied: Extract is not isolated THC/CBD; different doses and species.
Clinical interpretation: Model finding, not a recommendation for use
Limitations and uncertainties: Not a pharmacokinetic interaction prediction.
Original sources for this finding: Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea. [BMED10716207]; Attenuation of cyclophosphamide-induced taste aversions in mice by prochlorperazine, delta 9-tetrahydrocannabinol, nabilone and levonantradol. [BMED2997807]; Protective Effects of Cannabis sativa on chemotherapy-induced nausea in a rat: Involvement of CB1 receptors. [BMED35861135]
THC – clinically investigated
Finding ID: B0230
Type of result: Clinical evidence – context-specific
Observation: Historical studies reported symptomatic antiemesis with THC during chemotherapy; no specific change in chemotherapy pharmacokinetics can be inferred.
Mechanism: Antiemetic supportive treatment
Study type: Historical controlled antiemetic studies
Context studied: Orr: 55 people receiving chemotherapy including cyclophosphamide, 5-FU and doxorubicin; do not count the 1980/81 reports independently. No isolated cyclophosphamide pharmacokinetic effect.
Clinical interpretation: Context-specific evidence
Limitations and uncertainties: Combination regimens; antiemesis is neither tumour efficacy nor general combination safety.
Original sources for this finding: Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. [BMED6271846]; Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. [BMED6254456]
References and access status
[V2_LABEL_D0406] CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE FOR INJECTION) INJECTION, POWDER, FOR SOLUTION [HISUN PHARMACEUTICALS USA, INC.]
Original source / bibliographic reference
Authors: Hisun Pharmaceuticals USA, Inc.
Year: 2026
Source type: Official US SPL / DailyMed
Source access – 23 October 2026: Source destination was accessible when checked.
Bibliographic attribution or source identity cross-checked.
[BMED42202974] Cannabidiol alleviates chemotherapy-induced cognitive decline and neuropathology.
Original source / bibliographic reference
Authors: Madan S, El-Khatib SM, Prathigudupu A, Avalos HC, Ahmed F, Piomelli D, Chan A, Gupta K, Jung KM, Acharya MM.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.1016/j.canlet.2026.218612
PMID: 42202974
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED42076110] CBD Promotes Structural and Functional Epithelial Restoration and Alleviates Inflammation in a Mouse Model of Interstitial Cystitis.
Original source / bibliographic reference
Authors: Peskar D, Kerec Kos M, Tavčar Š, Lakota K, Kojc N, Veranič P, Erman A.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.3390/pharmaceutics18040458
PMID: 42076110
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED41508393] Intravesical Cannabidiol for Inflammation and Pain in Interstitial Cystitis/Bladder Pain Syndrome via TLR4/NF-κB and TRPV1 Modulation.
Original source / bibliographic reference
Authors: Piao JJ, Kim S, Lee HJ, Zhu GQ, Jeon KH, Park SH, Guan RL, Tian WJ, Xin ZC, Kim SW, Bae WJ.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.5534/wjmh.250152
PMID: 41508393
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED41595541] Cytotoxicity of Cannabinoids in Combination with Traditional Lymphoma Chemotherapeutic Drugs Against Non-Hodgkin's Lymphoma.
Original source / bibliographic reference
Authors: Omer S, Mansour M, Pondugula SR, Dhanasekaran M, Matz B, Khan O, Boothe D.
Year: 2025
Source type: Publication; title and abstract reviewed
DOI: 10.3390/biomedicines14010003
PMID: 41595541
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED33477420] Assessment of Cannabidiol and Δ9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma.
Original source / bibliographic reference
Authors: Andradas C, Byrne J, Kuchibhotla M, Ancliffe M, Jones AC, Carline B, Hii H, Truong A, Storer LCD, Ritzmann TA, Grundy RG, Gottardo NG, Endersby R.
Year: 2021
Source type: Publication; title and abstract reviewed
DOI: 10.3390/cancers13020330
PMID: 33477420
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED35861135] Protective Effects of Cannabis sativa on chemotherapy-induced nausea in a rat: Involvement of CB1 receptors.
Original source / bibliographic reference
Authors: Elgohary R, Salama A, Omara EA.
Year: 2023
Source type: Publication; title and abstract reviewed
DOI: 10.1111/fcp.12821
PMID: 35861135
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED10716207] Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea.
Original source / bibliographic reference
Authors: Limebeer CL, Parker LA.
Year: 1999
Source type: Publication; title and abstract reviewed
DOI: 10.1097/00001756-199912160-00009
PMID: 10716207
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED2997807] Attenuation of cyclophosphamide-induced taste aversions in mice by prochlorperazine, delta 9-tetrahydrocannabinol, nabilone and levonantradol.
Original source / bibliographic reference
Authors: Landauer MR, Balster RL, Harris LS.
Year: 1985
Source type: Publication; title and abstract reviewed
DOI: 10.1016/0091-3057(85)90567-2
PMID: 2997807
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED6271847] Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin.
Original source / bibliographic reference
Authors: Riggs CE, Egorin MJ, Fuks JZ, Schnaper N, Duffey P, Colvin OM, Aisner J, Wiernik PH, Bachur NR.
Year: 1981
Source type: Publication; title and abstract reviewed
DOI: 10.1002/j.1552-4604.1981.tb02581.x
PMID: 6271847
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED6271846] Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine.
Original source / bibliographic reference
Authors: Orr LE, McKernan JF.
Year: 1981
Source type: Publication; title and abstract reviewed
DOI: 10.1002/j.1552-4604.1981.tb02578.x
PMID: 6271846
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED6254456] Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.
Original source / bibliographic reference
Authors: Orr LE, McKernan JF, Bloome B.
Year: 1980
Source type: Publication; title and abstract reviewed
DOI: 10.1001/archinte.140.11.1431
PMID: 6254456
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.
Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility
Cyclophosphamide and cannabinoids: documented findings, evidence, sources and data gaps. Research information for discussion with your doctor or pharmacist.